• Profile
Close

Endoscopic submucosal dissection for superficial proximal esophageal neoplasia is highly successful

Annals of Surgery Nov 21, 2017

Zhang YQ, et al. - An inquiry was set up with regard to the consequences of endoscopic submucosal dissection (ESD) for superficial proximal esophageal neoplasia. It was deduced that ESD was a safe and a very effective treatment option for the superficial proximal esophageal neoplasia. It displayed a 100% 5-year disease-specific survival rate.

Methods

  • Researchers enrolled 102 consecutive patients with 106 lesions who underwent ESD from February 2009 to July 2015 at the Zhongshan Hospital, Fudan University in Shanghai, China.
  • They gauged the en bloc and pathologically complete resection rates, complication rate, incidence of esophageal stricture after ESD, disease-specific, and overall survival rates.

Results

  • Herein, the mean age was 62 (45-84) years with 100% en bloc resection rate.
  • The mean operation time was 48 (10-144) minutes. It was noted that the mean diameter of the resected tumors was 2.9 (1.2-6.5) cm.
  • The pathological diagnoses were discovered to be high-grade intraepithelial dysplasia in 45 (42.5%) lesions, and the rest were squamous cell carcinoma with staging of intraepithelial in 18 (17.0%), lamina propria in 13 (12.3%), muscularis mucosa in 16 (15.1%), SM1 in 10 (9.4%), and SM2 or deeper in 4 (3.8%) of the lesions.
  • The R0 resection rates were 94.3% (100/106).
  • No delayed bleeding occurred.
  • Findings revealed successful closure of two small perforations with clips.
  • Symptomatic esophageal strictures in 17 (16.7%) patients underwent treatment via endoscopic balloon dilation with a mean of 4 (1-14) times and 88.2% (15/17) success.
  • The yielded data suggested further treatments of esophagectomy or chemoradiotherapy for patients with SM1 or deeper neoplasia or incomplete resection.
  • Three cases (2.9%) reported local recurrence.
  • Fifteen patients were lost to follow-up.
  • Five-year overall survival rate was discovered to be 98% and disease-specific survival rate was 100%.
  • The mean follow-up time was determined to be 33.6 months.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay